Intensity Therapeutics (INTS) Net Cash Flow (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Net Cash Flow came in at -$1.7 million in Q1 2026, down 0.9% YoY from -$1.7 million in Q1 2025, and down 134.53% on a QoQ basis from $4.9 million in Q4 2025.
Intensity Therapeutics (INTS) Net Cash Flow (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Net Cash Flow data on file, last reported at -$1.7 million in Q1 2026.
- Quarterly Net Cash Flow fell 0.9% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (up 242.69% YoY) and the FY2025 annual result came in at $9.3 million, up 256.4% from the prior year.
- Net Cash Flow slipped to -$1.7 million in Q1 2026, from $4.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $6.6 million in Q3 2023 to a low of -$4.2 million in Q2 2024.
- A 5-year average of $418199.3 and a median of -$480000.0 in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow sank 778.54% — and 2025, when it soared 2628.12%.
- Tracing INTS's Net Cash Flow over 5 years: stood at -$1.6 million in 2022, then surged by 213.93% to $1.9 million in 2023, then tumbled by 110.31% to -$192000.0 in 2024, then soared by 2628.12% to $4.9 million in 2025, then sank by 134.53% to -$1.7 million in 2026.
- The last three Net Cash Flow figures came in at -$1.7 million (Q1 2026), $4.9 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | -716,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -716,000.00 |
| Jun 30, 2026 | -716,000.00 |
| Mar 31, 2026 | -1.68 Mn |
| Mar 31, 2026 | -1.68 Mn |
| Dec 31, 2025 | 4.85 Mn |
| Dec 31, 2025 | 4.85 Mn |
| Sep 30, 2025 | 4.85 Mn |
| Sep 30, 2025 | 4.85 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Mar 31, 2025 | -1.66 Mn |
| Mar 31, 2025 | -1.66 Mn |
| Dec 31, 2024 | -192,000.00 |
| Dec 31, 2024 | -192,000.00 |
| Sep 30, 2024 | -459,000.00 |
| Sep 30, 2024 | -459,000.00 |
| Jun 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | -4.22 Mn |
| Mar 31, 2024 | -1.10 Mn |
| Mar 31, 2024 | -1.10 Mn |